glp-1/glp-2 dual agonist The action of tirzepatide on various organs. GLP-1: Mechanisms of action and therapeutic

Therapeutic Use: Investigated for immune-mediated diseases such as: Immune thrombocytopenia (ITP) where platelets are destroyed by the immune system

(2021) 22(1):e13112

Kidney Med

Updated June 27, 2014

These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids

Adv Drug Deliv Rev